SCHEMBL805215

SCHEMBL805215

CN[C@@H](Cc1ccc2ccccc2c1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MME P08473 7/20 0.61
ACE P12821 5/20 0.61
CPA1 P15085 2/20 0.61
ACE2 Q9BYF1 2/20 0.61
CA2 P00918 1/20 0.55
PIN1 Q13526 2/20 0.55
MMP9 P14780 2/20 0.53
MMP8 P22894 2/20 0.53
FCER2 P06734 1/20 0.52
ALB P02768 1/20 0.50
IL2 P60568 1/20 0.50
CTSL P07711 1/20 0.50
CTSB P07858 1/20 0.50
CTSS P25774 1/20 0.50
CTSK P43235 1/20 0.50
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
HTR2B P41595 1/20 0.50
TACR1 P25103 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8895051 1.00 MME (0.61) MMEACECPA1ACE2CA2
SCHEMBL30498632 1.00 MME (0.61) MMEACECPA1ACE2CA2
SCHEMBL10071066 1.00 MME (0.61) MMEACECPA1ACE2CA2
SCHEMBL29981964 1.00 MME (0.61) MMEACECPA1ACE2CA2
SCHEMBL31532286 0.90 MME (0.57) MMEACECPA1ACE2CA2
SCHEMBL31532305 0.90 MME (0.57) MMEACECPA1ACE2CA2
SCHEMBL23016727 0.88 MME (0.60) MMEACECPA1ACE2PIN1
SCHEMBL10442191 0.88 MMP9 (0.53) MMEACECPA1ACE2MMP9
SCHEMBL8300313 0.88 MMP9 (0.53) MMEACECPA1ACE2MMP9
SCHEMBL7986637 0.88 MMP9 (0.53) MMEACECPA1ACE2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 US claimed
WO-2025070731-A1 PEPTIDEPEPTIDE ペプチドリーム株式会社 2025-04-03 WO disclosed
WO-2025070720-A1 PEPTIDE ペプチドリーム株式会社 2025-04-03 WO disclosed
US-20240218014-A1 SYNTHESIS OF A CYCLIC PEPTIDE JANSSEN PHARMACEUTICA NV (BE) 2024-07-04 US disclosed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 US disclosed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 US disclosed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 US disclosed
US-20230203098-A1 HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE JCR PHARMACEUTICALS CO., LTD. (JP) 2023-06-29 US disclosed
WO-2019164987-A1 HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF SEATTLE GENETICS, INC. (US) 2019-08-29 WO disclosed
US-20170158706-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-06-08 US disclosed
US-8889712-B2 IAP antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2014-11-18 US disclosed
US-20140323435-A1 Thienopyrimidine Inhibitors of Atypical Protein Kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-10-30 US disclosed
US-20120251459-A1 SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2012-10-04 US disclosed
US-20120071329-A1 METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES GLAXOSMITHKLINE LLC (US) 2012-03-22 US disclosed
US-20110251089-A1 METHODS FOR SYNTHESIS OF ENCODED LIBRARIES GLAXOSMITHKLINE (US) 2011-10-13 US disclosed
US-7989395-B2 Methods for identifying compounds of interest using encoded libraries GLAXOSMITHKLINE LLC (US) 2011-08-02 US disclosed
US-7935658-B2 Methods for synthesis of encoded libraries PRAECIS PHARMACEUTICALS, INC. (US) 2011-05-03 US disclosed
US-20090062147-A1 Methods for synthesis of encoded libraries PRAECIS PHARMACEUTICALS INCORPORATED (US) 2009-03-05 US disclosed
WO-1998045262-A1 PSEUDO-PEPTIDE COMPOUNDS AS ANTAGONISTS OF NEUROKININES MENARINI RICERCHE S.P.A. (IT) 1998-10-15 WO disclosed
US-5610140-A ANALGESICS, ANTIINFLAMMTORY AGENTS; TREATMENT OF ASTHMA CORTECH, INC. (US) 1997-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240218014-A1 SYNTHESIS OF A CYCLIC PEPTIDE VIP, QPCT, PTMS MME 406/4885ACE 1672/4885CPA1 126/4885
US-20110251089-A1 METHODS FOR SYNTHESIS OF ENCODED LIBRARIES RNGTT, DTYMK, DUT MME 562/4885ACE 421/4885CPA1 1976/4885
US-20230203098-A1 HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE TFRC, SLC3A2, SLC7A1 MME 549/4885ACE 2747/4885CPA1 1148/4885
US-20140323435-A1 Thienopyrimidine Inhibitors of Atypical Protein Kinase C PRKCQ, PRKDC, PRKACA MME 4557/4885ACE 2290/4885CPA1 3415/4885
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP MME 220/4885ACE 458/4885CPA1 660/4885
US-20170158706-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C PRKCQ, PRKDC, PRKACA MME 4557/4885ACE 2290/4885CPA1 3415/4885
US-20120251459-A1 SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN ENGASE, LGMN, DNPEP MME 7/4885ACE 343/4885CPA1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.